Precision Medicine to Profile Cancer through Circulating Tumor DNA: Clinical Applications and Future Perspectives
A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cell and Gene Therapy".
Deadline for manuscript submissions: closed (30 November 2019) | Viewed by 6579
Special Issue Editor
Interests: breast cancer; molecular oncology
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
A new methodology is being developed that relies on circulating tumor DNA (ctDNA). ctDNA is released into the blood stream when cells die. From time to time, cancer cells die from while a tumor is growing. ctDNA can be detected by drawing the blood plasma from patients during treatment or during the cancer staging process. Explosive advances in the field of cancer research have given rise to an array of mutated DNA sequences indicative of cancer cells. Testing blood plasma for cancer-specific DNA sequences represents the frontier of cancer diagnostics and treatment selection. Topics for this Special Issue include the following:
- Editorial: Utility of circulating tumor DNA for personalized cancer therapy;
- Circulating tumor DNA for drug selection and dynamic monitoring in advanced non-small cell lung cancer;
- Circulating tumor DNA for the management of anti-EGFR therapy in colorectal cancer;
- Circulating tumor DNA in advanced breast cancer: a new tool for drug selection;
- Circulating tumor DNA and the treatment of castration-resistant prostate cancer;
- Circulating tumor DNA: a new potential diagnostic approach for the big killers.
Prof. Daniele Generali
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- breast cancer
- prostate cancer
- colon cancer
- lung cancer
- rare cancer
- circulating tumor DNA
- precision medicine
- personalized cancer therapy
- drug selection and monitoring
